Abrams succeeds interim CFO Richard Narido, who will continue to support the company’s financial function and other projects.
NRx Pharmaceuticals recently appointed Michael Abrams as its permanent chief financial officer.
Abrams succeeds interim CFO Richard Narido, who will continue to support the company’s financial function and other projects, NRx said in a news release.
“Mike’s combination of public-company CFO experience in the biotechnology sector, together with investment-banking expertise, is ideally suited to NRx’s needs as we aim to become a revenue-generating, profitable biotechnology company,” said Dr. Jonathan Javitt, chairman, CEO and chief scientist of NRx Pharmaceuticals. “Additionally, we thank Rich for his outstanding service to the company as our interim CFO and look forward to his ongoing contributions as HOPE Therapeutics continues to grow its business.”
Abrams is a senior finance professional with almost three decades of experience as an executive officer, investment banker, director and senior advisor, which includes serving as the chief financial officer of Arch Therapeutics, RiseIT Solutions and FitLife Brands.
Abrams has deep experience across multiple functional areas such as financial operations, accounting, mergers and acquisitions, financial engineering, capital raising and shareholder communications, according to NRx.
He earned his MBA with honors from the University of Chicago Booth School of Business following his BBA with honors from the University of Massachusetts at Amherst, where he was named a William F. Field alumni scholar.
“I’m delighted to join NRx at this critical juncture in the company’s evolution,” Abrams said in a news release. “Evolving from a pre-revenue biotechnology company into a profitable enterprise is both a tremendous opportunity and challenge. I look forward to helping grow the company with the NRx team.”